The overall goal of our research is to understand the molecular mechanisms that underlie pathologic manifestations of scleroderma (SSc). Although etiology of SSc is still poorly understood, there is increasing evidence that inflammation directly contributes to the pathological vascular remodeling in SSc-associated pulmonary hypertension (SSc-PAH) and likely also plays a role in other complications. Published literature indicates that signaling pathways induced by endoplasmic reticulum (ER) stress and unfolded protein response (UPR) can initiate and propagate inflammation. We observed a significant increase of ER stress/UPR markers, which correlated with increase of inflammatory mediators (IL-6) in peripheral blood mononuclear cells (PBMCs) obtained from SSc-PAH patients. We have also noted that presence of HLAB35, which is associated with increased risk of PAH, induces ER stress/UPR in cultured endothelial cells, and correlates with elevated levels of ER strss/UPR markers in patient PBMCs. Furthermore, an ongoing study has revealed that in endothelial cells HLA-B35 synergizes with selected TLR (Toll-like receptor) agonists in upregulation of inflammatory cytokines and chemokines. Based on these novel observations we propose the following hypothesis: ER stress and UPR play a pathogenic role in SSc-PAH by sensitizing endothelial and immune cells to TLR agonists resulting in exacerbation of inflammatory responses. HLA-B35 may further intensify the disease process by contributing to endothelial cell dysfunction, as well as to activation of immune system in patients with PAH. To test these hypotheses and to gain additional insights into the molecular pathways underlying SSc-PAH, we propose the following specific aims.
Aim 1 : To determine the role of ER stress/UPR and HLA-B35 in endothelial cell function.
Aim 2 : To determine the role of ER stress/UPR and HLA-B35 in activation of immune cells.
Aim 3 : To determine the prevalence of HLAB35 allele and to perform genetic analyses of ER stress/UPR genes in IcSSc.
This study will lead to new knowledge on the vascular and immune mechanisms contributing to pulmonary hypertension in patients with SSc. Furthermore, these studies may result in characterization of novel disease markers and genetic associations, and ultimatily may provide logical targets for therapeutic interventions.
|Stifano, Giuseppina; Sornasse, Thierry; Rice, Lisa M et al. (2018) Skin Gene Expression Is Prognostic for the Trajectory of Skin Disease in Patients With Diffuse Cutaneous Systemic Sclerosis. Arthritis Rheumatol 70:912-919|
|Franks, Jennifer M; Cai, Guoshuai; Whitfield, Michael L (2018) Feature specific quantile normalization enables cross-platform classification of molecular subtypes using gene expression data. Bioinformatics 34:1868-1874|
|Apostolidis, Sokratis A; Stifano, Giuseppina; Tabib, Tracy et al. (2018) Single Cell RNA Sequencing Identifies HSPG2 and APLNR as Markers of Endothelial Cell Injury in Systemic Sclerosis Skin. Front Immunol 9:2191|
|Fleury, Michelle; Belkina, Anna C; Proctor, Elizabeth A et al. (2018) Increased Expression and Modulated Regulatory Activity of Coinhibitory Receptors PD-1, TIGIT, and TIM-3 in Lymphocytes From Patients With Systemic Sclerosis. Arthritis Rheumatol 70:566-577|
|Moll, Matthew; Christmann, Romy B; Zhang, Yuqing et al. (2018) Patients with systemic sclerosis-associated pulmonary arterial hypertension express a genomic signature distinct from patients with interstitial lung disease. J Scleroderma Relat Disord 3:242-248|
|Meiners, Silke; Evankovich, John; Mallampalli, Rama K (2018) The ubiquitin proteasome system as a potential therapeutic target for systemic sclerosis. Transl Res 198:17-28|
|Rice, Lisa M; Mantero, Julio C; Stratton, Eric A et al. (2018) Serum biomarker for diagnostic evaluation of pulmonary arterial hypertension in systemic sclerosis. Arthritis Res Ther 20:185|
|Cheong, Fei-Ying; Gower, Adam C; Farber, Harrison W (2017) Changes in gene expression profiles in patients with pulmonary arterial hypertension associated with scleroderma treated with tadalafil. Semin Arthritis Rheum 46:465-472|
|Yamashita, Takashi; Asano, Yoshihide; Taniguchi, Takashi et al. (2017) Glycyrrhizin Ameliorates Fibrosis, Vasculopathy, and Inflammation in Animal Models of Systemic Sclerosis. J Invest Dermatol 137:631-640|
|Rice, Lisa M; Mantero, Julio C; Stifano, Giuseppina et al. (2017) A Proteome-Derived Longitudinal Pharmacodynamic Biomarker for Diffuse Systemic Sclerosis Skin. J Invest Dermatol 137:62-70|
Showing the most recent 10 out of 70 publications